This disclosure relates to new tetracyclic compounds that may be used to modulate a histamine receptor in an individual. The compounds in one embodiment are tetracyclic[4,3-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
Exceptional Rate Enhancements and Improved Diastereoselectivities through Chelating Diamide Coordination in Intramolecular Alkene Hydroaminations Catalyzed by Yttrium and Neodymium Amido Complexes
Tactics for the asymmetric preparation of 2-azabicyclo[3.1.0]hexane and 2-azabicyclo[4.1.0]heptane scaffolds
作者:Andrzej Wolan、Mohamad Soueidan、Angèle Chiaroni、Pascal Retailleau、Sandrine Py、Yvan Six
DOI:10.1016/j.tetlet.2011.03.026
日期:2011.5
In this contribution, two methods are presented for the removal of benzyl-type protecting groups attached to the nitrogen atom of 2-azabicyclo[3.1.0]hexane and 2-azabicyclo[4.1.0]heptane systems. The first, based on the Polonovski reaction, is suitable for [3.1.0] systems. The second relies on an elimination process, starting from derivatives of O-methyl phenylglycinol, and is more general in terms